Tryptophan News and Research

RSS

Tryptophan is one of the 20 standard amino acids, as well as an essential amino acid in the human diet.

Biochemists solve puzzle of putrid camel pee to unearth potential target for treating sleeping sickness

Biochemists from Trinity College Dublin have solved an old mystery as to the cause of especially smelly camel urine, with implications for the millions of people affected by African parasites called trypanosomes.

17 Nov 2016

Maternal serum levels of nicotinamide linked to child’s risk of atopic eczema

Infants whose mothers had a higher level of a particular type of vitamin B during pregnancy have a lower risk of eczema at age 12 months, new Southampton research has shown.

23 Sep 2016

Research findings could provide framework for understanding fertilization mechanism

A Japanese research group has determined the crystal structure of the JUNO protein, an egg surface protein essential for fertilization. These structure-based mutational analyses elucidated a mechanism of the interaction between egg (JUNO protein) and sperm (IZUMO1) on a molecular level.

9 Aug 2016

Biochemists design genetic poison pill to thwart coxsackievirus B3

It has a funny name - coxsackievirus - but there's nothing funny about how this tiny germ and its close relatives sicken their hosts.

18 Jul 2016

Study demonstrates role of leukocyte activation receptor CD69 in development of psoriasis

Scientists at the Centro de Investigaciones Cardiovasculares Carlos III have defined the key role of an immune-system receptor in the development of psoriasis, suggesting that it could serve as a therapeutic target for the control of this disease.

5 Jul 2016

Prenatal mild viral assault may cause central nervous system malfunctions in children

Babies born to mothers whose immune systems had to grapple with a viral assault -- even a mild one -- have increased risk of brain and central nervous system abnormalities, according to a new study.

2 Jun 2016

Innovative strategy can reverse symptoms in neurodegenerative diseases

Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders worldwide and cause untold suffering to millions of patients and their families. Treatments for these diseases are limited, and no cures exist. Now, a new study describes an innovative strategy that reverses symptoms in these neurodegenerative diseases - at least in fruit flies which had been genetically altered to model the diseases.

26 Apr 2016

Nutritional supplements can enhance effectiveness of antidepressants

An international evidence review has found that certain nutritional supplements can increase the effectiveness of antidepressants for people with clinical depression.

26 Apr 2016

Altered metabolism of two essential amino acids helps drive development of glioblastoma

The altered metabolism of two essential amino acids helps drive the development of the most common and lethal form of brain cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

2 Apr 2016

Study reveals direct regulatory role of serotonin in rheumatoid arthritis

For the first time, serotonin (5-hydroxytryptamine, 5-HT) has been directly implicated in the pathophysiology of rheumatoid arthritis (RA). Although 5-HT is predominantly known as a neurotransmitter within the central nervous system, new evidence points to additional important functions for serotonin in the periphery.

10 Mar 2016

Food-based proteins can help address child malnutrition in developing countries

Contrary to popular belief among world relief workers, children in developing countries may not be eating enough protein, which could contribute to stunted growth, a Johns Hopkins-directed study suggests.

24 Feb 2016

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

1 Dec 2015

Melatonin and the circadian rhythm: an interview with Professor Kennaway, University of Adelaide

The production of melatonin is controlled by a part of the brain called the suprachiasmatic nucleus (SCN) and its timing fine-tuned by our exposure to light during the morning.

20 Oct 2015

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Lexicon updates drug development progress, reports 2014 financial results

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2014.

4 Mar 2015

Vitamin D, omega-3 fatty acids may optimize brain serotonin concentrations and function

Although essential marine omega-3 fatty acids and vitamin D have been shown to improve cognitive function and behavior in the context of certain brain disorders, the underlying mechanism has been unclear. In a new paper published in FASEB Journal by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute, serotonin is explained as the possible missing link tying together why vitamin D and marine omega-3 fatty acids might ameliorate the symptoms associated with a broad array of brain disorders.

27 Feb 2015

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University.

8 Jan 2015